trump glp 1 coverage President Donald unveils major cuts to weight-loss drug prices through new deals Trump's GLP-1 deals leaves questions

Compare early results with Wegovy and Mounjaro.

Heart failure patients could be the next group to benefit from GLP-1 agonists, which are currently approved for the treatment of diabetes and obesity.

Summary Retatrutide, a triple agonist now in phase 3 trials, has the potential to become the most effective pharmacological treatment for obesity while also offering substantial benefits in T2D management and other cardiometabolic risk factors.

See which states cover GLP-1 drugs under Medicaid in 2025.

Interestingly, this raises important points in regard to the need to hold GLP-1 RAs prior to concurrent EGD and colonoscopy procedures and the number of days needed to hold these agents, if necessary

Moreover, the combined GLP-1 mechanisms of weight loss and delayed carbohydrate absorption may also be the key drivers of remission of type 2 diabetes and reduced cardiovascular events found by GLP-1 analogues.